Kronos Bio Inc (KRON)
$0.98
+0.02
(+2.08%)▲
Insights on Kronos Bio Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 79.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 335.8%
Performance
- $0.96$1.00$0.98
2.04%
Downside
Day's Volatility :4.0%
Upside
2.0%
- $0.73$2.29$0.98
25.41%
Downside
52 Weeks Volatility :68.08%
Upside
57.21%
Returns
| Period | Kronos Bio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -11.71% | 0.5% | 0.0% |
6 Months | 11.36% | 11.7% | 0.0% |
1 Year | -26.59% | 6.2% | 2.2% |
3 Years | -96.28% | 13.5% | -23.0% |
Highlights
Market Capitalization | 57.7M |
Book Value | $2.7 |
Earnings Per Share (EPS) | -1.95 |
Wall Street Target Price | 4.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -994.36% |
Return On Assets TTM | -28.83% |
Return On Equity TTM | -55.84% |
Revenue TTM | 6.3M |
Revenue Per Share TTM | 0.11 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -115.1M |
Diluted Eps TTM | -1.95 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.54 |
EPS Estimate Next Year | -1.72 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.48 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 333.67%
Technicals Summary
Sell
Neutral
Buy
Kronos Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kronos Bio Inc | -17.65% | 11.36% | -26.59% | -96.28% | -96.38% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kronos Bio Inc | NA | NA | NA | -1.54 | -0.56 | -0.29 | NA | 2.7 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kronos Bio Inc | Buy | $57.7M | -96.38% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Omega Fund Management LLC
6.55%Bvf Inc
4.98%Vida Ventures Advisors, LLC
4.74%Perceptive Advisors LLC
3.01%Vanguard Group Inc
2.92%PARTNERS CAPITAL INVESTMENT GROUP, LLP
2.86%
Corporate Announcements
Kronos Bio Inc Earnings
Kronos Bio Inc’s price-to-earnings ratio stands at None
Read More
Company Information
kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Organization | Kronos Bio Inc |
Employees | 62 |
CEO | Dr. Norbert W. Bischofberger Ph.D. |
Industry | Health Technology |
